Oakwood Medical Investors IV

Portfolio Companies

AllianceCare (formerly Sunrise At-Home Senior Living, Inc.) provides visiting doctors (physician housecalls), rehabilitation therapy, private duty, and home healthcare services in more than seven states. The company operates 24 branch offices, and provides senior health services in more than 125 assisted and independent living facilities. Sunrise At-Home Senior Living is integrated into the current AllianceCare business structure and operates under the name AllianceCare At Home.

 

                 

EKOS Corporation is the world leader in providing ultrasound-assisted, fluid infusion catheters for diagnosis and therapy. The company's EKOS® Lysus® Peripheral Infusion System and EKOS® Micro-Infusion Catheter are FDA-cleared for the delivery of therapeutic agents, including clot-dissolving thrombolytics, into the peripheral vasculature of patients with peripheral arterial occlusions (PAO) and deep vein thrombosis (DVT). The EKOS Micro-Infusion Catheter is also cleared for the administration of contrast media into the brain.

 

EndoGastric Solutions, Inc. is a pioneer in endoluminal procedures for the treatment of upper gastrointestinal diseases, including gastroesophageal reflux disease (GERD) and obesity. EndoGastric Solutions' initial procedures involve modifying current open surgical and/or laparoscopic approaches using trans-oral access. The company designs and manufactures single use instruments that will enable incision-less procedures, and focus on clinically-based products for use by gastroenterologists and surgeons.

 

       

Favrille, Inc. (NasdaqNM: FVRL) is focused on the research, development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. Favrille's lead product candidate, FavId, is an immunotherapy treatment for indolent B-cell non-Hodgkin's lymphoma (or NHL) designed to stimulate a patient's immune system to mount a specific and sustained response against the disease.            

Lanx, Inc. specializes in systems and implants for all segments of spinal surgery.  Integrating leading technology, intellectual property and state-of-the-art engineering, each product is designed to simplify surgery and improve the quality of care for patients worldwide by providing surgeons with innovative spinal products.

MedVantx, Inc. has developed a proprietary point-of-care platform to automate and promote the dispensing of popular generic pharmaceuticals in physician offices. With the backing of the nation's major health plans, MedVantx is deploying its platform technology in the offices of primary care physicians to facilitate the use of gold standard generic pharmaceuticals as first-line therapy.

Mitralign, Inc. is developing an innovative, catheter-based method to effectively treat mitral regurgitation in patients suffering from Congestive Heart Failure. Mitralign's goal is to emulate the technique employed in traditional open heart surgical repair but in a far less invasive manner.

NovaVision, Inc. has developed an FDA-cleared, patented, non-invasive medical device that has been shown to restore vision in stroke, traumatic brain injury (TBI) or optic nerve injury survivors with central visual field deficits. The NovaVision device provides Vision Restoration Therapy™ (VRT). VRT is a rehabilitative, restorative therapy designed to help stroke and brain injury patients regain enough vision to independently perform more of their previously lost activities of daily life.

Sadra Medical (acquired by Boston Scientific Corporation) is dedicated to developing innovative new therapies for the treatment of aortic valve disease. By developing minimally invasive alternatives to traditional surgical valve replacement, the company seeks to help improve patient care and make valve replacement possible for broader range of patients.

Spherics, Inc. is an emerging pharmaceutical company focused on applying its proprietary oral drug delivery platform technologies to develop products with improved therapeutic profiles. The Company’s novel delivery technologies improve drug performance by increasing absorption and residence time in specific regions of the gastrointestinal tract.

TransMolecular, Inc. is committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat challenging diseases where there are inadequate pharmaceutical alternatives. The Company's lead product is a novel targeted anti-cancer therapeutic and imaging agent to treat adult recurrent glioma (brain tumors).